# Everlife Biomed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/everlife-biomed

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.everlifebiomed.com
- Latest round: Series A (Jun 23, 2025)
- Investors on record: 3

## About

Established in 2018 and based in Beijing, China, Everlife Biomed is a biotechnology company that engages in the research and development of Human-derived immune-exempt cell therapy products. In February 2019, it signed a cooperation agreement with Tsinghua University Medical School. In April 2021, it signed the first clinical experimental hospital. The CEO, Jianlin Liang, is a Ph.D. from the Tsinghua-Peking University Life Sciences Joint Center and the main inventor of the Sertoli cell core patent. The chief scientist officer, Jiakui Ji, is a professor at Tsinghua University, an expert in the field of stem cell differentiation, and the main inventor of the domestic patent of immune cell induction technology and PCT patent. The company's products can be categorized into rheumatoid arthritis cell injection, immune-exempt artificial pancreas, and assisted reproductive testing systems. It has developed immune-exempt drugs to protect transplanted cells or tissues from host attack, to treat autoimmune diseases, or as a carrier for transplanted cells. The company generates revenue from clinical-stage cell therapy products, licensing of immune-exempt technologies, and specialized diagnostic systems in reproductive and autoimmune health. In June 2025, Everlife Biomed raised Series A funding from new investors Yuanhe Capital and Innoangel Fund.

## Funding rounds

- Series A, Jun 23, 2025 — Innoangel Fund, Yuanhe Capital
- Angel, Feb 25, 2019 — Tsinghua Innovation Ventures

## Investors

- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Angel
- Innoangel Fund (https://capitalatlas.ai/funds/innoangel-fund) — Series A
- Yuanhe Capital — Series A